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Submission to the Committee
on the Ethics of Gene Therapy
by the Joint Ethico-Medical Committee of the
Catholic Union of Great Britain and the Guild of Catholic Doctors

The Catholic Union is a non-affiliated lay Organisation under the
Presidency of His Grace the Duke of Norfolk and The Guild of Catho lic
Doctors is an autonomous Bod y of approximate ly 1.000 practising British
Doctors. This Submisson is mad e by the Joint Ethico-Medical Committee
o n behalf of the two Bodies.
As Catholics we have a tradition of affirming human dignity under
contemporary co ndition s and we endorse; the generally accepted ethical
principles of justice and beneficence, and the autonomy of patients .
Although scientific di scove ry can be a legitimate end in itself where Man is
concerned we accept the principles of the Helsinki Declaration which state
inter alia: - "Concern for the interest of the subject must always prevail
over the interests of scie nce and society" (Principle /.5).
GENE THERAPY
We consider this de ve lopment to be exceedingly important and follow
with interest the decisions ta king place between Clinicians and Scientists in
this field both in the country and overseas. We hope that new therapeutic
possibilities will arise which could benefit patients, but there are dangers.
As a result of the science of molecular biology four thousa nd single gene
disorders have so far been id e ntified. In time a complete decoding of the
human genome may revea l the genetic predisposition for other diseases
including some which are multi-genetic .
Advances in conventional treatment have become available in recent
times, leading to sym ptomatic relief from some 12% of the inherited
diseases (e.g. Phen yl-ketonuria) and the partial relief of another 40% (e.g.
Cystic Fibrosis). slightly less than half of the known inherited diseases
cannot be substantially relieved by conventional medicine.
Tissue and organ transplantation may improve these figures. Examples
a re successful marrow tra nsp lantation for some of the inherited anaemias
a nd, more recentl y, lung transplantation for end stage sufferers of cystic
fibrosis. (Royal College of Physicians Conference on 'Ge ne Therapy' 1990).
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Clinical gene therap y is aimed at the replacement of d efecti ve genes and is
similar to organ transplantation. This technique can be applied to somatic
cells or to germ-line cell s. The consequences of germ line cell therapy would
be that the alterations would be transmitted to progen y, thus making a
profound ethical difference from somat ic cell therap y.

SINGLE GENE DISORDERS
For successful gene modification it is necessary that:
I.
2.
3.
4.

the gene and its regulatory region has been isolated.
the target ce ll for genetic m odifica tion is accessible.
a safe transfer syste m must be fo und . and
th ere must be a reaso nable prospect of th e lo ng te rm s urviva l of the new ce ll
popula tion. with it s beneficial exp ress ion .

We understand that so me of the disorders which might be treated in thi s
wa y when suitable techniques have been pe rfected include:
Some congenital immu ne deficiency di so rders
Thallassaemia
Phenylk e tonuria
Gauchers di sease
Lesc h-N y han di sease.

This is only the beginning of what could prove to be a substantial list.

ETHICAL CONSIDER A TIONS OF SOMA TIC CELL
GENE THERAPY
In ge neral term s, the ethical considerations are similar to tho se of tissue
or organ tra nspl a ntati o n . The re mu st be a ba la nce between risks and
benefits. and after the techniques have bee n pe rfected using animal model s.
including Public Health aspects. th ey may become applicable to human s.
We acknowledge that the first di so rd e rs t o be trea ted are th ose which are
currently fatal or profoundl y crippling but ca nnot exclude the poss ibilit y
that. with time. o th er conditions ma y legi tim a tel y benefit from ge ne
modification. An example of thi s co uld be hae m o phili a which ca n a lread y
be treated successfull y. The ri sk I be nefit ra ti o for ge ne therapy would ha ve
to be bett e r than th a t o f the present treatm e nt.
In this , it is not ed that the pa tient s will. for th e most pa rt. be in a position
to give consent o n their ow n be half. or. wi th children. by proxy. In genera l.
it seems to us. th e giving of co ns e nt o n be half of a minor wo uld require a
hi g her degree of ass ura nce of success and benefic ia l outcome than that
w hich would justify consent by adults on th eir ow n behalf. It is neither
et hica l nor lega l for a parent to give consent o n behalf of a c hild to any
procedure which is not in the ch ild 's own int e rest. We consider that th is. in
practice. exc lud es the ap plicatio n of ge ne therapy for reasons (such as
cosmetic or aesthetic) other than for th e treatment of pathological
cond iti ons.
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It also seems to us not inconceivable that children could sue parents for
any damage done to them, as an individual , as a result of an intervention by
t he parent.

ETHICAL CONSIDERATIONS OF GERM LINE CELL
GENE THERAPY
There are major scientific and ethical differences between somatic (nonreproducible) and germ line (reproducible) therapy. The latter results in a
permanent alteration of an individual's genetic composition which would
be transmitted by them to future generations. The first and obvious factor is
that such a step is irreversible.
.
A particular problem relating to autonomy arises from the impossibility
of obtaining the consent of future or developing affected individuals. Even
if an assumption is made that individuals would wish to be spared a disease ,
t he re would need to be a wide measure of agreement in Society that only
those diseases of the most crippling nature would justify the risks of
permanently altering the human genome.
We also consider that alteration of the human genome, which would
affect future generations, would be unjust as it denies such generations their
autonomy and may not accord with full human dignity. In other words,
eve n if it could be foreseen that germ-line cell therapy might become an
acceptable form of treatment for disease, such that the parents might be
entitled to consent to it for the child's benefit and to its own good, there
remains the impossibilit y of obtaining the consent of future generations to
alterations affecting the human 'genetic library'. We have no right to
assume that their wishes necessarily correspond with our own. and it
thereb y becomes impossible to envisage a situation where we would be
en titled to assume their consent.
The long term effects of alterations to the genome cannot be foretold.
The removal of defective genes (such as sickle cell anaemia) might lower
community protection factors (in this case against malaria).
In addition. whilst some of the common disorders , such as diabetes,
atherosclerosis and hypertension. which are known to have genetic
predispositions. could arguably be alleviated by gene therapy we consider
thi s to be unjustifiable when alternative therapy or alterations in life style
achieve comparable res ults.
Further difficulties are lik e ly to arise with germ line therapy if, as it seems
likely. it would be inevitabl y linked with screening during antenatal
development with a view to terminating those pregnancies in which the
genetic transfer appeared imperfec t. We think it probable that at the early
stages of germ line gene therapy such screening might be a condition of the
patient being accepted for treatment. This would, of itself. be incompatible
with a woman's autonomy and should not be required. although there is at
prese nt no experimental basis for treating polygenetic conditions, there is at
least a theoretical po ssib ilit y that this could be used not only for the
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treatment of maladies but for such manipUlations as attempts to improve
human intelligence , physique or life span. this would be analagous to
eugenics which is open to grave abuse and could lead to great human
injustice . We doubt if there ever could be agreement in Society on those
human characteristics which should be enhanced or those which should be
eliminated and attempts to take scientific control of human evolution seem
to be little more than scientific hubris. We have already expressed our view
that such attempts would be ethically unacceptable.

CONTROL OF GENE THERAPY RESEARCH AND APPLICATION
It is implicit in the establishment of your Committee that Society has an
interest in regulating research and treatment by genetic modification. The
issue is one of such magnitude and public interest that we would consider it
inappropriate that it should be controlled by the existing Ethics
Committees of Hospitals , Post Graduate Institutes or Universities.
Although National Bodies such as the Royal Colleges clearly make a major
contribution, particularly with their appreciation of scientific and medical
issues, a more broadly based regulatory Body which full y reflects Society's
interests need s to be established.
There is also a need for National Governments to work with others
towards international conventions. Work has already begun on this with
the European Community. (Recommendation No . 934 (1982) on Genetic
Engineering from the 33rd ordinary session of the Parliamentary Assembly
of the Council of Europe.)
We acknowledge that advances in molecular biology might perhaps lead
to more extensive embryo screening in In Vitro Fertilisation programmes
for an increasing number of inherited disorders. Within our moral
tradition , however, there are particular difficulties in the use of In- Vitro
Fertilisation as a method of reproduction.
In- Vitro Fertilisation is not in accord with our view that the gift of life
should normally come as a result of mutual self gift of parents. The role of
third parties (as technician or as donor) in what can correctly be regarded as
asexual reproduction has not been determined and we are concerned at the
possibility that new life conceived in this way may be seen as a 'product'
under human control. This in our tradition would not do full justice to the
standing of the individual. It has always been our view that human life has
an inestimable value which is not lost through sickness or aging or inborn
imperfection. Furthermore, it has always been the Catholic position that
human life demands respect from its first origins to its natural end (Domlln
Vitae. Vatican Polyglot Press, 1988).
There is here, perhaps , a further argument for a national Medical Ethics
Committee with wide representation and public accountability. Such a
Body should be answerable to Parliament through the Secretary of State
and the proposed Licensing Authority for Embryology and Human
Fertilisation could, with suitable amendments , be a model for such a
November. 1990
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regulatory and licensing body. There is an obvious need for scientists of
adequate standing to be advising this Body, but an equal need for advice
from other traditions in Society including the main religious denominations
and systematic philosophies as well as informed la y opinion . A regulatory
Body would enjoy more public confidence if its composition was not
predominantly medical and scientific .
Society has a major interest in future developme nts of the manipulation
of the human genome and a Regulatory Body could only properly be seen
as accountable to Society if it were established on the authority of
Parliament.
II remains our conviction that H'hilst scientific ach'ancement is a
legitimate objective in its mrn right, Il'hen applied to Man science must
alwars remain at his service and that human dignitr remains paramount.
We conclude, that somatic cell therapy will offer substantial benefits.
suitably controlled. Germ line cell therap y, however. s hould no t be
contemplated until somatic cell therapy has proved successful fora suitable
length of time, perhaps one generation . We do not consider germ line cell
therapy ethically justifiable at the present time. if ever.

Signed hr
NORFOLK
President of the Catholic Union of' Great Britain
J . C. GALLAGHER
Master o f'the Guild of' Catholic Doc{()rs
I. M . JESSI MAN
Chairman of' the Joint £t hico- IHedical Co 111 111 ill 1'1'

Th e Committee I\ 'ishes to record its appreciation {() Dr. A nthOn!' Cole,
FRCPE. DCH. Il'ho ;I'rote the initial drafi of'this {JapeI'.
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